Galenum s.r.o.

At Galenum s.r.o. in Bratislava, the clinical trial portfolio is centered on cardiovascular diseases. The studies focus on conditions such as atherosclerotic cardiovascular disease, cardiovascular disease, and risk reduction in patients with established heart and vascular disease.

• Research on lowering cardiovascular risk in people with established heart and vessel disease
• Studies aimed at preventing major events such as heart attack, stroke, and urgent revascularization
• Trials exploring new treatment options for patients with elevated lipoprotein(a) and related risk

Overall, the site is involved in evaluating new therapies that may improve prevention, treatment effectiveness, and long-term outcomes for patients with serious cardiovascular conditions.

A major area of research at this hospital/clinic is atrial fibrillation, with trials designed to reduce the risk of stroke and systemic embolism. These studies are especially relevant for patients who need better options for preventing clot-related complications.

• Testing new approaches to prevent stroke in people with atrial fibrillation
• Comparing emerging treatments with established care to assess safety and effectiveness
• Focusing on patients who are not suitable for standard oral anticoagulation

This research reflects a strong interest in improving both protection from serious complications and the overall balance of benefit and bleeding risk in atrial fibrillation care.

The site also supports studies in chronic heart failure and hyperlipidemia, including research on cholesterol-related risk and heart function. These trials are designed to better understand how new therapies may help patients with persistent cardiovascular problems.

• Evaluating treatment options for chronic heart failure
• Assessing therapies that lower LDL cholesterol and other lipid-related risk factors
• Investigating whether new medicines can improve cardiovascular outcomes in high-risk patients

By combining heart failure and lipid-focused research, Galenum s.r.o. contributes to studies that aim to improve long-term disease control and reduce future cardiovascular events.